In vitro studies using the CRISPR/Cas9 technology confirmed that, compared with Ctrl-Cas9 cells, HIPK2-knockout significantly decreases cell sensitivity to 5-Fluorouracil (5-FU) and oxaliplatin (OXA) [71], drugs frequently used in the treatment of colon cancer, including stage II cases [100]. The gene discussed is HIPK2; the disease is colonic neoplasm.